SF3B1 and myelodysplastic syndrome: Malcovalti et al. highlight the positive independent prognostic value of SF3B1 mutations in sideroblastic categories only, while, in MDS with excess blasts, the mutation did not have a significant effect on survival and risk of disease progression [29,30].